Last reviewed · How we verify
Intranasal glugagon
Intranasal glucagon, marketed by A.O.U. Città della Salute e della Scienza, is a rapid-acting treatment designed to raise blood sugar levels in patients with hypoglycemia. Its key strength lies in its mechanism of action, which stimulates the liver to release stored glucose, providing a fast and effective response. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | Intranasal glugagon |
|---|---|
| Also known as | Baqsimi® |
| Sponsor | A.O.U. Città della Salute e della Scienza |
| Drug class | Hormonal |
| Target | Liver |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Pipeline indications
Common side effects
Key clinical trials
- Stimulation Test With Intranasal Glucagon for Corticotroph, Somatotroph and Antidiuretic Axes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intranasal glugagon CI brief — competitive landscape report
- Intranasal glugagon updates RSS · CI watch RSS
- A.O.U. Città della Salute e della Scienza portfolio CI